United Therapeutics Corporation (UTHR)
| Market Cap | 23.16B +16.4% |
| Revenue (ttm) | 3.15B +2.5% |
| Net Income | 1.31B +5.5% |
| EPS | 27.95 +9.0% |
| Shares Out | 42.89M |
| PE Ratio | 19.44 |
| Forward PE | 20.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 844,070 |
| Open | 542.64 |
| Previous Close | 543.40 |
| Day's Range | 527.89 - 546.14 |
| 52-Week Range | 409.07 - 609.35 |
| Beta | 0.49 |
| Analysts | Buy |
| Price Target | 651.15 (+20.58%) |
| Est. Earnings | Oct 28, 2026 |
About UTHR
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of tre... [Read more]
Financial Performance
In 2025, United Therapeutics's revenue was $3.18 billion, an increase of 10.61% compared to the previous year's $2.88 billion. Earnings were $1.33 billion, an increase of 11.68%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for UTHR stock is "Buy." The 12-month stock price target is $651.15, which is an increase of 20.58% from the latest price.
News
LifeSci upgrades Liquidia to Buy on overhang clearing settlement
LifeSci Capital upgraded Liquidia (LQDA) to Outperform from Market Perform with a $59 price target. The company announced a settlement with United Therapeutics (UTHR) that resolves all six pending law...
Liquidia price target raised to $33 from $30 at Wells Fargo
Wells Fargo raised the firm’s price target on Liquidia (LQDA) to $33 from $30 and keeps an Equal Weight rating on the shares after the company and United Therapeutics (UTHR)…
Liquidia upgraded at BTIG after ‘much more favorable’ than expected settlement
As previously reported, BTIG upgraded Liquidia (LQDA) to Buy from Neutral with a $70 price target after the company announced it reached a global settlement with United Therapeutics (UTHR) to…
Liquidia Stock (LQDA) Pops as $380.7M Deal Ends Legal Battle with United Therapeutics
Liquidia ($LQDA) stock jumped about 47% in Wednesday’s pre-market trading after the biopharmaceutical company focused on respiratory and vascular diseases announced a $380.7 million settlement with Un...
Liquidia to pay $175M UTHR after settlement agreement
Liquidia (LQDA) and United Therapeutics (UTHR) reached a global settlement agreement that resolves all pending litigation between the companies. YUTREPIA, or treprostinil, inhalation powder will remai...
Liquidia up 40% to $37.59 after settlement agreement with United Therapeutics
17:57 EDT Liquidia (LQDA) up 40% to $37.59 after settlement agreement with United Therapeutics (UTHR)
Liquidia announces a global settlement agreement with United Therapeutics
Liquidia (LQDA) announced that it has entered into a global settlement agreement with United Therapeutics (UTHR) that resolves all pending litigation between the companies. Importantly, YUTREPIA, or t...
United Therapeutics presents new data at CHEST 2026 meeting
United Therapeutics (UTHR) announced that two oral and five poster presentations will be presented across its commercial and development portfolio at the CHEST 2026 Annual Meeting hosted by the Americ...
United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that two oral and five poster presenta...
United Therapeutics price target raised to $708 from $677 at RBC Capital
RBC Capital raised the firm’s price target on United Therapeutics (UTHR) to $708 from $677 and keeps an Outperform rating on the shares as part of a broader research note…
United Therapeutics price target raised to $566 from $515 at Morgan Stanley
Morgan Stanley raised the firm’s price target on United Therapeutics (UTHR) to $566 from $515 and keeps an Equal Weight rating on the shares. The firm adjusted its models for…
Liquidia downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded Liquidia to Outperform from Strong Buy with a price target of $53, down from $106. Liquidia’s (LQDA) Delaware court loss on United Therapeutics’ (UTHR) ‘327 patent removes…
United Therapeutics’ path to $1,000 ‘just got easier,’ says Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer Saunders tells investors in a research note that United Therapeutics’ (UTHR) path to $1,000 “just got easier” following the patent infringement ruling over Liqu...
United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court ...
Liquidia slumps after US court rules for United Therapeutics in patent fight
Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by rival United Therapeutics , dealing a major blow to the treatment's commer...
United Therapeutics Transcript: Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Fourteen new therapies are being launched for pulmonary and fibrotic diseases, with a focus on disruptive innovation, robust financial stewardship, and a transformative organ manufacturing program targeting commercial launch by 2030. AI-driven drug development and a high-efficiency culture underpin rapid growth and industry leadership.
United Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
A major strategic shift is underway, expanding from orphan pulmonary hypertension to large pulmonary fibrosis markets, with strong clinical data supporting new launches and ambitious revenue targets. Multiple product formulations and sales force expansions are planned, while regulatory confidence remains high for upcoming approvals.
United Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A major clinical and commercial transformation is underway, with best-in-class pulmonary fibrosis data, a rapidly expanding addressable market, and 14 product launches planned through 2029. Launch readiness, polypharmacy strategies, and a $500 million stock buyback highlight strong momentum and confidence in reaching $50–$100 billion in revenue by the early 2030s.
United Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
Fourteen new products are set for rapid launch, targeting $50–100 billion in annual pharma revenue and addressing a million-patient market. Key innovations include once-daily and coughless inhalers, with strong IP protection and major investments in manufacturing and xenotransplantation.
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company will utilize the rema...
United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the suppleme...
United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that company executives will provide overviews and updates during fir...
United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four oral presentations and four p...
United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the FDA has accepted the New Drug...
United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF study evaluating the use of Tyvaso® (trepr...